PatientsVille.com Logo


Progestin Medical Research Studies

Up-to-date List of Progestin Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Progestin Medical Research Studies

Rank Status Study
1 Recruiting Clinical Trial on the Effects of Progestin-based Contraception in the Genital Tract of HIV-infected and Uninfected Women
Conditions: HIV;   Contraception
Interventions: Drug: Depo-Medroxyprogesterone Acetate;   Drug: Progestin Contraceptive (Jadelle)
Outcome Measures: HIV viral load in the genital tract of HIV-infected women before and after initiation of Progestin-containing contraception;   HIV viral load in the genital tract of HIV-infected women by contraceptive type;   Impact of the type of Progestin-containing contraception (injectable versus implant) on inflammatory/immune markers in the genital tract women.;   Contraceptive efficacy in HIV-infected women;   Interaction of Progesting-based hormonal contraception and antiretroviral therapy
2 Recruiting Effect of Progestin-Induced Withdrawal Bleed on Ovulation Induction Cycles With Clomiphene Citrate
Conditions: Polycystic Ovary Syndrome;   Infertility
Intervention: Drug: Progestin
Outcome Measures: Clinical pregnancy rate per ovulation;   cumulative pregnancy rate;   ovulation rate;   ongoing pregnancy rate;   miscarriage rate;   multiple pregnancy rate;   endometrial thickness
3 Not yet recruiting The Effect of Different Types of Progestin on Sleeping of Menopausal Women
Condition: Menopausal and Postmenopausal Disorders
Interventions: Drug: 1mg 17 beta-estradiol;   Drug: Dydrogesterone;   Drug: micronized progesterone
Outcome Measures: Improving of sleeping quality (assessed by the PSQI score);   The side effects comparing the 2 arms.;   The climacteric symptoms comparing the 2 arms.
4 Recruiting Clomiphene Citrate Fast-Track Protocol for Fertility Treatment in Women With PCOS
Conditions: Polycystic Ovary Syndrome;   Infertility
Interventions: Drug: Progestin;   Drug: Clomiphene Citrate
Outcome Measures: Clinical pregnancy confirmed by pelvic ultrasound;   Time to first ovulation;   Time to clinical pregnancy;   Live birth
5 Recruiting Study of Immediate Start of Progestin Contraceptives in Medical Abortion
Condition: Contraception
Intervention: Other: Timing of Contraceptive Initiation in Medical Abortion
Outcome Measures: Medical Abortion Failure;   Repeat Pregnancy
6 Not yet recruiting Virexxa (Sodium Cridanimod) in Conjunction With Progestin Therapy in Patients With Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma
Condition: Recurrent or Persistent Endometrial Carcinoma
Intervention: Drug: Sodium cridanimod
Outcome Measures: Objective Response Rate;   Progression-free survival;   Time to response;   Time to progression;   Overall survival;   Overall Disease Control Rate
7 Recruiting Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
Conditions: Relapsing-remitting Multiple Sclerosis;   Secondary-progressive Multiple Sclerosis;   Primary-progressive Multiple Sclerosis
Interventions: Drug: estriol;   Other: Placebo;   Drug: Norethindrone;   Other: Progestin Placebo
Outcome Measures: Change from baseline in cognitive function assessed by Paced Serial Addition Test (PASAT).;   Change from baseline in cognitive function as assessed by cognitive evoked potentials, measured in milliseconds.;   Change from baseline in standard MS outcome measures.;   Determine safety by assessing the number of subjects with adverse events with combination treatment as compared to placebo.;   Change from baseline in cognitive function as assessed by a brief battery of cognitive tests.
8 Recruiting The Impact of Vaginal and IM Progestins on the Cervix
Conditions: Preterm Birth;   Short Cervical Length
Outcome Measures: Biomarkers;   Cervical sonographic changes;   Protein Expression;   Cervical cytokines;   Individual cytokines;   Cervical MMPs;   Single nucleotide polymorphisms
9 Unknown  Progestagens for the Tertiary Prophylaxis of Preterm Delivery
Conditions: Premature Birth;   Neonatal Complications
Interventions: Drug: 17 alpha-hydroxy progesterone caproate;   Drug: micronized Progesterone;   Other: Control
Outcome Measures: Preterm delivery (37 weeks of gestation);   Delivery <32, <35 wks;   Hospital admissions before delivery;   Gestational age at delivery;   Birth-weight centile;   NICU admission;   days of NICU admission;   days of oxygen supply;   composite neonatal complications;   congenital neonatal anomalies;   congenital neonatal malformations
10 Recruiting Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast Cancer
Condition: Carcinoma Breast Stage IV
Outcome Measure: RECIST 1.1
11 Unknown  Progestin Treatment for Endometrial Stromal Cells in Adenomyosis
Condition: Endometriosis
Outcome Measure:
12 Unknown  Initiating Contraception After Emergency Contraception From Pharmacy
Condition: Emergency Contraception
Interventions: Other: rapid access to contraceptive service;   Other: one month progestogen only pill
Outcome Measures: self-reported uptake of effective ongoing contraception (not condoms);   pharmacy recruitment rates;   completeness (quality) of data recorded by pharmacists (numbers of women attending for EC,demographics of all attendees- age, ethnicity etc);   proportion of women who agree to participate who can be successfully contacted
13 Unknown  Combined Hormonal Versus Progestin Only Contraception During Lactation
Condition: Lactation
Outcome Measure:
14 Unknown  Is Cerazette Use Before Nexplanon Insertion Predictive for Bleeding Pattern?
Condition: Bleeding
Interventions: Drug: Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon);   Drug: Etonogestrel 68 mg subdermal implant
Outcome Measures: The total number of bleeding days per 90 days reference period in women using Cerazette before Nexplanon and in women starting Nexplanon without preceding POP;   The number of bleeding episodes according to WHO definitions
15 Unknown  Norplant and Irregular Bleeding/Spotting
Conditions: Endometrial Bleeding;   Periodontal Disease
Intervention: Drug: doxycycline
Outcome Measure:
16 Recruiting A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding for Secondary Amenorrhea
Condition: Secondary Amenorrhea
Intervention: Drug: Progesterone
Outcome Measures: • The proportion of subjects at Cycle 3 Day 24 ± 1 day on active treatment compared to placebo with complete secretory activity on endometrial biopsy.;   • The proportion of subjects at Cycle 3 Day 24 ± 1 day on active treatment compared to placebo with total secretory activity (defined as the aggregate of partial and complete secretory activity) on endometrial biopsy.
17 Recruiting Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist
Condition: Dysfunctional Uterine Bleeding
Intervention: Drug: Medroxyprogesterone 17-Acetate
Outcome Measures: Amount of bleeding with or without use of medroxyprogesterone acetate after initiation of gonadrotropin-releasing hormone agonist therapy,;   the number of days of bleeding, nausea, bloating, and pelvic pain
18 Not yet recruiting Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin
Condition: Uterine Leiomyoma
Interventions: Drug: Dienogest;   Drug: Goserelin;   Drug: Desogestrel
Outcome Measures: Leiomyoma Volume;   Pictorial Blood Assessment Chart (PBAC) Score Reduction;   Number of episodes of vaginal bleeding
19 Recruiting Comparison of Levonorgestrel Intrauterine System, Copper T Intrauterine Device and Oral Contraceptives on Life Quality
Condition: Contraceptive Methods Comparison
Interventions: Drug: YASMIN® (Drospirenone/Ethinyl Estradiol);   Device: The Copper-T is an intrauterine device (IUD);   Device: levonorgestrel-releasing system
Outcome Measures: Lipid profile (HDL,VLDL,IDL,LDL,Lp(a),VLDL)Lng-ius users, Copper-iud users and combined oral contraceptive users (composite measurement);   coagulation parameters(composite measurement)
20 Recruiting Uterine Electrical Activity Before and After Progesterone Treatment for Preterm Labor
Condition: Preterm Labor
Interventions: Drug: Experimental: Vaginal progesterone;   Drug: Experimental: Topical progesterone;   Drug: Experimental: Intramuscular progesterone
Outcome Measures: Inhibition of uterine electromyographic (EMG) activity by various formulations of progesterone.;   Effects of progesterone on uterine EMG activity and preterm birth

These studies may lead to new treatments and are adding insight into Progestin etiology and treatment.

A major focus of Progestin research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Progestin